Cancer cell membrane cloaking nanoparticles for targeted co-delivery of doxorubicin and PD-L1 siRNA

References

• Zhen X, Cheng P, Pu K. Recent advances in cell membrane–camouflaged nanoparticles for cancer phototherapy. Small. 2019;15:1804105.
   PubMed Web of Science ®Google Scholar
• Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013;65:71–79.
   PubMed Web of Science ®Google Scholar
• Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev. 2015;91:3–6.
   PubMed Web of Science ®Google Scholar
• Zhu JY, Zheng DW, Zhang MK, et al. Preferential cancer cell self-recognition and tumor self-targeting by coating nanoparticles with homotypic cancer cell membranes. Nano Lett. 2016;16:5895.
   PubMed Web of Science ®Google Scholar
• Li R, He Y, Zhang S, et al. Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment. Acta Pharmaceutica Sinica B. 2018;8:14–22.
   PubMed Web of Science ®Google Scholar
• Yoo JW, Irvine DJ, Discher DE, et al. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov. 2011;10:521–535.
   PubMed Web of Science ®Google Scholar
• Balmert SC, Little SR. Biomimetic delivery with micro- and nanoparticles. Adv Mater. 2012;24:3757–3778.
   PubMed Web of Science ®Google Scholar
• Hu CM, Fang RH, Luk BT, et al. 'Marker-of-self' functionalization of nanoscale particles through a top-down cellular membrane coating approach. Nanoscale. 2013;5:2664–2668.
   PubMed Web of Science ®Google Scholar
• Luk BT, Hu CM, Fang RH, et al. Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. Nanoscale. 2013;6:2730–2737.
   Web of Science ®Google Scholar
• Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364:2119–2127.
   PubMed Web of Science ®Google Scholar
• Hamdy S, Molavi O, Ma Z, et al. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine. 2008;26:5046–5057.
   PubMed Web of Science ®Google Scholar
• Hu CM, Zhang L, Aryal S, et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci USA. 2011;108:10980–10985.
   PubMed Web of Science ®Google Scholar
• Fang RH, Hu CM, Luk BT, et al. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 2014;14:2181–2188.
   PubMed Web of Science ®Google Scholar
• Iero M, Valenti R, Huber V, et al. Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ. 2008;15:80–88.
   PubMed Web of Science ®Google Scholar
• Teo PY, Yang C, Whilding LM, et al. Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing. Adv Healthcare Mater. 2015;4:1180–1189.
   Web of Science ®Google Scholar
• Yue C, Yang M, Tian Q, et al. IGFBP7 is associated to prognosis and could suppress cell survival in cholangiocarcinoma. Artif Cells Nanomed Biotechnol. 2018;46:817–825.
   PubMed Web of Science ®Google Scholar
• Yang C, Vu-Quang H, Husum DMU, et al. Theranostic poly(lactic-co-glycolic acid) nanoparticle for magnetic resonance/infrared fluorescence bimodal imaging and efficient siRNA delivery to macrophages and its evaluation in a kidney injury model. Nanomed Nanotechnol Biol Med. 2017;13:2451–2462.
   PubMed Web of Science ®Google Scholar
• Biagiotti S, Paoletti MF, Fraternale A, et al. Drug delivery by red blood cells. IUBMB Life. 2011;63:621–631.
   PubMed Web of Science ®Google Scholar
• Aryal S, Hu CM, Fang RH, et al. Erythrocyte membrane-cloaked polymeric nanoparticles for controlled drug loading and release. Nanomedicine (London, England). 2013;8:1271–1280.
   PubMed Web of Science ®Google Scholar
• Hu CM, Fang RH, Wang KC, et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature. 2015;526:118–121.
   PubMed Web of Science ®Google Scholar
• Rao L, Bu LL, Cai B, et al. Cancer cell membrane-coated upconversion nanoprobes for highly specific tumor imaging. Adv Mater. 2016;28:3460–3466.
   PubMed Web of Science ®Google Scholar
• Fang RH, Luk BT, Hu CM, et al. Engineered nanoparticles mimicking cell membranes for toxin neutralization. Adv Drug Deliv Rev. 2015;90:69–80.
   PubMed Web of Science ®Google Scholar
• Hu CM, Fang RH, Copp J, et al. A biomimetic nanosponge that absorbs pore-forming toxins. Nat Nanotech. 2013;8:336–340.
   PubMed Web of Science ®Google Scholar
• Fang RH, Kroll AV, Gao W, et al. Cell membrane coating nanotechnology. Adv Mater. 2018;30:1706759.
   PubMed Web of Science ®Google Scholar
• Fang RH, Jiang Y, Fang JC, et al. Cell membrane-derived nanomaterials for biomedical applications. Biomaterials. 2017;128:69–83.
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhao P, Luo Z, et al. Cancer cell membrane-biomimetic nanoparticles for homologous-targeting dual-modal imaging and photothermal therapy. ACS Nano. 2016;10:10049–10057.
   PubMed Web of Science ®Google Scholar
• Gao W, Hu CM, Fang RH, et al. Surface functionalization of gold nanoparticles with red blood cell membranes. Adv Mater. 2013;25:3549–3553.
   PubMed Web of Science ®Google Scholar
• Hu CM, Fang RH, Zhang L. Erythrocyte-inspired delivery systems. Adv Healthcare Mater. 2012;1:537–547.
   Web of Science ®Google Scholar
• Pulido J, Kottke T, Thompson J, et al. Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat Biotechnol. 2012;30:337–343.
   PubMed Web of Science ®Google Scholar
• Castle JC, Kreiter S, Diekmann J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 2012;72:1081–1091.
   PubMed Web of Science ®Google Scholar
• Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7:771–782.
   PubMed Web of Science ®Google Scholar
• Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J Cell Biol. 2010;188:759–768.
   PubMed Web of Science ®Google Scholar
• Iurisci I, Cumashi A, Sherman AA, et al. Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. Anticancer Res. 2009;29:403–410.
   PubMed Web of Science ®Google Scholar
• Khaldoyanidi SK, Glinsky VV, Sikora L, et al. MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions. J Biol Chem. 2003;278:4127–4134.
   PubMed Web of Science ®Google Scholar
• Glinsky VV, Glinsky GV, Glinskii OV, et al. Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res. 2003;63:3805–3811.
   PubMed Web of Science ®Google Scholar